Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
Status:
Recruiting
Trial end date:
2030-09-01
Target enrollment:
Participant gender:
Summary
This phase III trial compares survival in urothelial cancer patients who stop immune
checkpoint inhibitor treatment after being treated for about a year to those patients who
continue treatment with immune checkpoint inhibitors. Immunotherapy with monoclonal
antibodies, such as avelumab, durvalumab, pembrolizumab, atezolizumab, and nivolumab, may
help the body's immune system attack the cancer, and may interfere with the ability of tumor
cells to grow and spread. Stopping immune checkpoint inhibitors early may still make the
tumor shrink and patients may have similar survival rates as the patients who continue
treatment. Stopping treatment early may also lead to fewer treatment-related side effects, an
improvement in mental health, and a lower cost burden to patients.